Graham Capital Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Graham Capital Management’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$306K	Sell	686 -507	-42%	-$236K	0.01%	808
2025 Q4	$541K	Buy	+1,193	New	+$514K	0.01%	603
2025 Q1	–	Sell	-569	Closed	-$229K	–	1541
2024 Q4	$229K	Buy	+569	New	+$264K	﹤0.01%	1034
2024 Q2	–	Sell	-2,357	Closed	-$985K	–	1392
2024 Q1	$985K	Buy	2,357 +530	+29%	+$224K	0.02%	428
2023 Q4	$743K	Buy	+1,827	New	+$675K	0.02%	467
2023 Q3	–	Sell	-1,144	Closed	-$403K	–	1306
2023 Q2	$403K	Buy	+1,144	New	+$385K	0.01%	607
2022 Q4	–	Sell	-14,195	Closed	-$4.11M	–	1370
2022 Q3	$4.11M	Sell	14,195 -88	-0.6%	-$25.3K	0.16%	67
2022 Q2	$4.02M	Buy	14,283 +11,624	+437%	+$3.11M	0.16%	78
2022 Q1	$693K	Buy	2,659 +223	+9%	+$52.9K	0.02%	438
2021 Q4	$534K	Buy	+2,436	New	+$474K	0.02%	160

Other funds holding VRTX

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Graham Capital Management's VRTX Position: Q1 2026 in Review

Graham Capital Management reduced its Vertex Pharmaceuticals (VRTX) stake by 42% in Q1 2026, selling an estimated $236K and leaving 686 shares worth $306K. The position accounts for 0.01% of the portfolio, ranked #808.

Graham Capital Management first reported a position in VRTX in Q4 2021 and has held it in 10 quarters since. The position peaked at $4.11M in Q3 2022. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

Graham Capital Management held 686 shares of Vertex Pharmaceuticals worth $306K as of Q1 2026.
Graham Capital Management sold 507 Vertex Pharmaceuticals shares in Q1 2026, an estimated $236K.
Vertex Pharmaceuticals made up 0.01% of Graham Capital Management's portfolio in Q1 2026, its #808 holding.
Graham Capital Management first reported a position in Vertex Pharmaceuticals in Q4 2021 and has held it in 10 quarters since.
Graham Capital Management's Vertex Pharmaceuticals position peaked at $4.11M in Q3 2022.
1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on Graham Capital Management's 13F filing for Q1 2026, filed 15 May 2026.